LYNDRA THERAPEUTICS
REINVENTING MEDICINES FOR A HEALTHIER WORLD
team
Dr Patricia Hurter
CEO | Member of the Board
Jessica Ballinger
President | Chief Operations Officer
Raymond
Knox
Chief Manufacturing Officer
Dr Richard Scranton
Chief MedicalOfficer
Dr Örn Almarsson
Chief TechnologyOfficer
Abigail
Jenkins
Chief Commercial & Business Officer
Susan
Birdsey
SVP, People & Culture
Jennifer
McGovern
SVP, Alliance & Program Management
Dr Mary Christian
SVP, Regulatory, Quality & Compliance
Dana
Vittum
VP, Finance
Dr Tyler
Grant
Sr Director, Engineering | Founding Employee
Dr Rosemary Kanasty
Director, Platform Discovery | Founding EmployeeBoard of Directors
Catherine B. Reynolds
Chair of the Board
Dr Robert Langer
Co-Founder | Member of the Board
Amy
Schulman
Executive Chair of the Board | Co-Founder
Dr Giovanni Traverso
Co-Founder| Member of the Board Dr Patricia Hurter
CEO | Member of the Board
Douglas Dachille
Member of the Board
Dr Zafrira Avnur
Member of the Board
Jillian Moo-Young
Member of the BoardCompany advisors
Dr Andrew Bellinger
Co-Founder | Advisor
Dr Bernard Silverman
Advisor
Dr Joga Gobburu
Advisor
Dr Edmund Harrigan
Advisor
Dr Thomas Laughren
Advisor
Dr Peter Belafsky
Advisor
Dr Ian Wilding
AdvisorCompany Timeline
Founded on technology developed within the MIT lab of Dr. Robert Langer in collaboration with the Bill & Melinda Gates Foundation
Platform and single agent preclinical in 2 species
($0.3 M NIH Grant)
Demonstrated gastric residence achievable with desired pharmacokinetics-single agent
($23 M Series A, $105 M AbbVie Partnership, $6 M NIH Grant(s), $4 M BMGF Grant)
Demonstrated once-weekly dosage form can safely reside in the stomach with predictable pharmacokinetics – single agent
($18 M NIH Grant(s), $13 M BMGF Grant)
Demonstrated once-weekly dosage form can safely reside in the stomach with predictable pharmacokinetics – two agents in one capsule and preliminary food effects
($60 M Series B, $122 M Gilead Partnership, $19M NIH Grant, $3 M DoD Grant)
Expanded pipeline, repeat dosing, and food effects
($2M BMGF Grant, $1M NIH Grant)
Initiating pivotal studies, expanding clinical pipeline, and scaling up commercial manufacturing
investors & partners
Previous
Next